Skip to main content

Breast Cancer

From the Literature, Breast Cancer, Dose Escalation/Reduction

Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

FDA Oncology Update, Breast Cancer

FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer

FDA Oncology Update, Breast Cancer

FDA Approves Margenza for the Treatment of Metastatic HER2-Positive Breast Cancer

Breast Cancer

Breast Cancer Year in Review Introduction

Breast Cancer

Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib

Breast Cancer

Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors

Breast Cancer

Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer

Breast Cancer

Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results

Breast Cancer

Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer

2
3
4
5
6
7
8

Page 5 of 11
Results 41 - 50 of 101